Efficacy and safety of panchgavya GHRIT along with flunarizine in prophylaxis for migraine patients: a comparitive study


  • Mohit Trivedi Department of Pharmacology, T.S.MISRA Medical College and Hospital, Lucknow, Uttar Pradesh, India
  • Vishal Dixit Department of Pharmacology, T.S.MISRA Medical College and Hospital, Lucknow, Uttar Pradesh, India
  • Syed Esam Mahmood Department of Community Medicine, Government Medical College, Banda, Uttar Pradesh, India
  • Sunil Kumar Mishra Ayurvedic Consultant, King George's Medical University, Lucknow, Uttar Pradesh, India
  • S. S. Keshari Department of Pharmacology, T.S. MISRA Medical College and Hospital, Lucknow, Uttar Pradesh, India




Flunarizine, Migraine, Panch gavya ghrit


Background: Propranolol and flunarizine have proven to be useful tools in migraine prophylaxis. This trial aims the comparison of the efficacy of flunarizine, flunarizine and placebo and flunarizine and panchgavya ghrit in migraine prophylaxis.

Methods: The present study was a prospective, randomized, open-label, blinded-endpoint trial. Patients with chronic migraine were randomized (1:1:1) to flunarizine and flunarizine and placebo and flunarizine and panchgavya ghrit in three treatment groups. The study was carried out in outdoor patients in the department of Psychiatry, T.S. Mishra Medical College and Hospital, Lucknow and K.G.M.U, Ayush Department, Lucknow after clearance from Institutional Ethical Committee. Data was analysed using SPSS software.

Results: The prevalence of migraine was found to be higher in the age group greater than 30 years and females. Overall there was more reduction in CGI scores in flunarizine with panchgavya ghrit and the other two groups equally at the end of 4, 6 8 and 10 weeks. Decrease in MIDAS score was observed after the therapy. Clinical Global Impression rating scale employed revealed that to start with subjects scored 7 which stands for pathology interfering in many life functions which reduced drastically in Group C as compared to Group B and Group A in descending order. Pain scales namely VAS (visual analogue scale), NPRS (Numeric Pain Rating Scale), VRS (verbal rating scale) when employed denoted there was decreased migraine frequency, decreased perception of pain, less intake of abortive medication consumed by subjects implying there were reduction in number of migraine days and there was decrease in the abortive medications taken for the same. Group C scored better on pain scales followed by Group B and Group A. Lower proportion of individuals in group C had Behavioural Toxicity and Neurological Side effects as compared to Group A and B.

Conclusions: Panch gavya ghrit when administered along with flunarizine was more efficacious and safe when compared with other two groups. However large multicentric RCTs of long duration and involving more number of subjects are required to ascertain these facts.


Lantéri-Minet M. The role of general practitioner in migraine management. Cephalalgia. 2008;28:1-8.

Vijayan S. Migraine: An expensive headache to the world. Available from: http://thelancetstudent.com/2008/03/16/ migraine-an-expensive-headache-to-the-globe/.

Ravishankar K. Barriers to headache care in India and effort to improve the situation. Lancet Neurol. 2004;3:564-7.

Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638-45.

Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-57.

Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine; 2005. Available at: http://www.aan.com/professionals/practice/guideline.

Bhavamisra, Bhavaprakasa, KR Srikantamoorthy, Krishnadas Academy Varanasi. 2000;33:306.

Agnivesa, Carakasamhita- Chikitsasthana 10/20, with the commentary of Cakrapanidatta- Varanasi Krishnadas academy, 2009;307.

Tiwari PV, Kasyapa Samhitha 2nd Ed, Chawkamba Viswabharati Varanasi. 2002;243.

Nighantu B, Srikantha Murthy RS. Krishnadas Academy, Varanasi, 1st Ed; 1998:470.

Nighantu B, Srikantha Murthy RS. Krishnadas Academy, Varanasi, 1st Ed; 1998:454.

Nighantu B, Srikantha Murthy RS. Krishnadas Academy, Varanasi, 1st Ed; 1998:473.

Panchagavya Ayurved Chikitsa, Ed. and Pub. by Gau-Vigyan Anusandhan Kendra, Devlapur-Nagpur, 3rd Ed; 2006:7:62.

Curds benefits, Side effects as per Ayurveda. Available from: Easyayurveda.com/2010/12/31/curds-benefits Last accessed 23-03-2017.

Koneru A. Journal of Pharmacy Research, Anticonvulsant Activity of Panchagavya Ghrita: a Poly-Herbal Ayurvedic formulation. 2009;2(5):795-7.

Achalia GS, Kotagle NR, Wadodkar SG, Dorle AK. Hepatoprotective activity of Panchagavya Ghrita against Carbontetrachloride induced Hepatotoxicity in rats, Indian Journal of Pharmacology. 2003;35:308-311.

Pawar A. Experimental evaluation of anti epileptic activity of Panchagavya Ghrita (PGG) and its effect on memory, 2013.

Diamond S, Kudrow L, Stevens J, Shapiro BD. Long-term study of propranolol in the treatment of migraine. Headache. 1982;22:268-71.

Martínez-Lage JM. Flunarizine (Sibelium) in the prophylaxis of migraine: an open, long-term, multicenter trial. Cephalalgia. 1988;8(8):15-20.

Sorensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia. 1986;6:7-14.

Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol versus propranolol versus placebo in common migraine prophylaxis: A double-blind multicenter trial. Acta Neurol Scand. 1984;69:1-8.

Neurological Disorders: Public health challenges. World Health Organization. 2006. Available at ogy/neurological_disorders_report_web.pdf Last accessed 23-03-2017.

Limmroth V, Kazarawa Z, Fritsche G, Diener HC. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. 1999;353:78.

Mauskop A. Complementary and alternative treatments for migraine. Drug Dev Res. 2008;68:424-7.

Witt CM, Reinhold T, Jena S, Brinkhaus B, Willich SN. Cephalalgia. 2008;28:334-45.

Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: A comprehensive efficacy review. Appl Psychophysiol Biofeedback. 2008;33:125-40.

Facco E, Liguori A, Petti F, Zanette G, Coluzzi F, De Nardin M, et al. Traditional acupuncture in migraine: A controlled, randomized study. Headache. 2008;48:398-407.

John PJ, Sharma N, Sharma CM, Kankane A. Effectiveness of yoga therapy in the treatment of migraine without aura: A randomized controlled trial. Headache. 2007;47:654-61.

Rossi P, Di Lorenzo G, Malpezzi MG, Faroni J, Cesarino F, Di Lorenzo C, et al. Prevalence, pattern and predictors of use of complementary and alternative medicine (CAM) in migraine patients attending a headache clinic in Italy. Cephalalgia. 2005;25:493-506.

Gogtay NJ, Bhatt HA, Dalvi SS, Kshirsagar NA. The use and safety of non-allopathic Indian medicines. Drug Saf. 2002;25:1005-19.

Eadie MJ. An 18th century understanding of migraine - Samuel Tissot (1728-1797) J Clin Neurosci. 2003;10:414-9.

MacLennan AH, Wii DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. 1996:347569-73.

Vaidya PB, Vaidya BS, Vaidya SK. Response to Ayurvedic therapy in the treatment of migraine without aura Int J Ayurveda Res. 2010;1(1):30-6.




How to Cite

Trivedi, M., Dixit, V., Mahmood, S. E., Mishra, S. K., & Keshari, S. S. (2017). Efficacy and safety of panchgavya GHRIT along with flunarizine in prophylaxis for migraine patients: a comparitive study. International Journal of Basic & Clinical Pharmacology, 6(4), 948–954. https://doi.org/10.18203/2319-2003.ijbcp20171110



Original Research Articles